An Open-label, Multi-center Phase II Study of Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Status: Recruiting
Location: See all (23) locations...
Intervention Type: Combination product, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Confirmed HCC based on histopathological findings from tumor tissues or radiologically findings.
• Must not have received prior systemic therapy for unresectable HCC.
• Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C.
• Child-Pugh Score class A.
• ECOG performance status of 0 or 1 at enrollment.
• At least 1 measurable lesion per RECSIT 1.1 guidelines
Locations
Other Locations
China
Research Site
RECRUITING
Beijing
Research Site
RECRUITING
Beijing
Research Site
RECRUITING
Beijing
Research Site
RECRUITING
Chengdu
Research Site
RECRUITING
Chongqing
Research Site
RECRUITING
Guangzhou
Research Site
RECRUITING
Guangzhou
Research Site
RECRUITING
Guangzhou
Research Site
RECRUITING
Guangzhou
Research Site
RECRUITING
Hangzhou
Research Site
RECRUITING
Hefei
Research Site
RECRUITING
Jinan
Research Site
RECRUITING
Nanjing
Research Site
RECRUITING
Nanjing
Research Site
RECRUITING
Ningbo
Research Site
RECRUITING
Shanghai
Research Site
NOT_YET_RECRUITING
Shanghai
Research Site
NOT_YET_RECRUITING
Taiyuan
Research Site
RECRUITING
Tianjin
Research Site
RECRUITING
Wenzhou
Research Site
RECRUITING
Wuhan
Research Site
RECRUITING
Xiamen
Research Site
RECRUITING
Zhengzhou
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2025-08-05
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 114
Treatments
Experimental: Single Arm
Durvalumab and Tremelimumab with Lenvatinib
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca